Rani Therapeutics Ownership 2024 | Who Owns Rani Therapeutics Now?


OverviewForecastRevenueFinancialsChartTranscripts

Institutional Ownership

12.21%

Insider Ownership

48.88%

Retail Ownership

38.91%

Institutional Holders

37.00

Rani Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC2.69%-685,30316,9562.54%2,131,292Mar 31, 2024
NAN FUNG GROUP HOLDINGS LTD1.94%1.42%493,584--1,535,046Mar 31, 2024
UNITED SERVICES AUTOMOBILE ASSOCIATION1.89%0.04%481,300--1,496,843Mar 31, 2024
ALPHABET INC.1.76%0.06%448,492--1,394,810Mar 31, 2024
STIFEL FINANCIAL CORP0.52%0.00%132,43482,168163.47%411,866Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.51%-130,90617,27715.20%407,223Mar 31, 2024
BANK OF AMERICA CORP /DE/0.49%-124,50510,2468.97%387,211,000Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.28%0.00%70,30026,60060.87%219,000Mar 31, 2024
BLACKROCK INC.0.25%-63,583--197,743Mar 31, 2024
LASRY MARC0.25%0.17%62,887--195,579Mar 31, 2024
KING LUTHER CAPITAL MANAGEMENT CORP0.22%0.00%56,129--174,561Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.20%0.00%51,500--160,165Mar 31, 2024
MOTCO0.19%0.01%48,129--149,681Mar 31, 2024
BROWN ADVISORY INC0.13%0.00%33,911--105,463Mar 31, 2024
STATE STREET CORP0.13%-33,742--104,938Mar 31, 2024
ALPHA SQUARE GROUP S, LLC0.13%0.19%33,401-25,545-43.34%103,877Mar 31, 2024
XR SECURITIES LLC0.12%0.00%30,90030,900100.00%96,099Mar 31, 2024
NORTHERN TRUST CORP0.10%-25,9886,56733.81%80,823Mar 31, 2024
HRT FINANCIAL LP0.09%0.00%22,58722,587100.00%70,000Mar 31, 2024
LAFAYETTE INVESTMENTS, INC.0.08%0.01%19,893--61,868Mar 31, 2024

Rani Therapeutics's largest institutional shareholder is VANGUARD GROUP INC, holding 2.69% of the company's total share outstanding, currently valued at $2.13M. The top 10 institutional shareholders own together 10.56% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
NAN FUNG GROUP HOLDINGS LTD1.94%1.42%493,584--1,535,046Mar 31, 2024
ALPHA SQUARE GROUP S, LLC0.13%0.19%33,401-25,545-43.34%103,877Mar 31, 2024
LASRY MARC0.25%0.17%62,887--195,579Mar 31, 2024
ALPHABET INC.1.76%0.06%448,492--1,394,810Mar 31, 2024
UNITED SERVICES AUTOMOBILE ASSOCIATION1.89%0.04%481,300--1,496,843Mar 31, 2024
ISLAY CAPITAL MANAGEMENT, LLC0.04%0.02%9,611--29,890Mar 31, 2024
ACTIVEST WEALTH MANAGEMENT0.04%0.01%9,800--30,478,000Mar 31, 2024
LAFAYETTE INVESTMENTS, INC.0.08%0.01%19,893--61,868Mar 31, 2024
MOTCO0.19%0.01%48,129--149,681Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.20%0.00%51,500--160,165Mar 31, 2024
XR SECURITIES LLC0.12%0.00%30,90030,900100.00%96,099Mar 31, 2024
CHOREO, LLC0.08%0.00%19,813--61,618Mar 31, 2024
KING LUTHER CAPITAL MANAGEMENT CORP0.22%0.00%56,129--174,561Mar 31, 2024
PRIME CAPITAL INVESTMENT ADVISORS, LLC0.05%0.00%13,882-2,800-16.78%43,173Mar 31, 2024
STIFEL FINANCIAL CORP0.52%0.00%132,43482,168163.47%411,866Mar 31, 2024
HRT FINANCIAL LP0.09%0.00%22,58722,587100.00%70,000Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.28%0.00%70,30026,60060.87%219,000Mar 31, 2024
BROWN ADVISORY INC0.13%0.00%33,911--105,463Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.00%0.00%1,239-1,069-46.32%3,853Mar 31, 2024
ALLWORTH FINANCIAL LP0.01%0.00%3,119--9,701,000Mar 31, 2024

The largest Rani Therapeutics shareholder by % of total assets is NAN FUNG GROUP HOLDINGS LTD. The company owns 493.58K shares of Rani Therapeutics (RANI), representing 1.42% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
STIFEL FINANCIAL CORP0.52%0.00%132,43482,168163.47%411,866Mar 31, 2024
XR SECURITIES LLC0.12%0.00%30,90030,900100.00%96,099Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.28%0.00%70,30026,60060.87%219,000Mar 31, 2024
HRT FINANCIAL LP0.09%0.00%22,58722,587100.00%70,000Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.51%-130,90617,27715.20%407,223Mar 31, 2024
VANGUARD GROUP INC2.69%-685,30316,9562.54%2,131,292Mar 31, 2024
CITADEL ADVISORS LLC0.06%-14,40014,400100.00%44,784Mar 31, 2024
BANK OF AMERICA CORP /DE/0.49%-124,50510,2468.97%387,211,000Mar 31, 2024
CITADEL ADVISORS LLC0.04%-10,03210,032100.00%31,200Mar 31, 2024
JPMORGAN CHASE & CO0.05%-12,6868,988243.05%39,454Mar 31, 2024
CITADEL ADVISORS LLC0.03%-7,4007,400100.00%23,014Mar 31, 2024
NORTHERN TRUST CORP0.10%-25,9886,56733.81%80,823Mar 31, 2024
UBS GROUP AG0.01%-3,0003,000100.00%9,330Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-10310.98%320,000Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD--3--9Mar 31, 2024
RHUMBLINE ADVISERS0.00%-312--970,000Mar 31, 2024
BLACKROCK INC.0.25%-63,583--197,743Mar 31, 2024
STATE STREET CORP0.13%-33,742--104,938Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.0.04%-9,116--28,351,000Mar 31, 2024
ALLWORTH FINANCIAL LP0.01%0.00%3,119--9,701,000Mar 31, 2024

As of Mar 31 2024, Rani Therapeutics's largest institutional buyer is STIFEL FINANCIAL CORP. The company purchased 82.17K stocks of RANI, valued at $411.87K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ALPHA SQUARE GROUP S, LLC0.13%0.19%33,401-25,545-43.34%103,877Mar 31, 2024
SIMPLEX TRADING, LLC0.01%-1,364-7,772-85.07%4,000Mar 31, 2024
PRIME CAPITAL INVESTMENT ADVISORS, LLC0.05%0.00%13,882-2,800-16.78%43,173Mar 31, 2024
MORGAN STANLEY0.01%-2,451-2,750-52.87%7,623Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.00%0.00%1,239-1,069-46.32%3,853Mar 31, 2024
IAG WEALTH PARTNERS, LLC----1,005-100.00%-Mar 31, 2024
NAN FUNG GROUP HOLDINGS LTD1.94%1.42%493,584--1,535,046Mar 31, 2024
LASRY MARC0.25%0.17%62,887--195,579Mar 31, 2024
ALPHABET INC.1.76%0.06%448,492--1,394,810Mar 31, 2024
UNITED SERVICES AUTOMOBILE ASSOCIATION1.89%0.04%481,300--1,496,843Mar 31, 2024
ISLAY CAPITAL MANAGEMENT, LLC0.04%0.02%9,611--29,890Mar 31, 2024
ACTIVEST WEALTH MANAGEMENT0.04%0.01%9,800--30,478,000Mar 31, 2024
LAFAYETTE INVESTMENTS, INC.0.08%0.01%19,893--61,868Mar 31, 2024
MOTCO0.19%0.01%48,129--149,681Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.20%0.00%51,500--160,165Mar 31, 2024
CHOREO, LLC0.08%0.00%19,813--61,618Mar 31, 2024
KING LUTHER CAPITAL MANAGEMENT CORP0.22%0.00%56,129--174,561Mar 31, 2024
BROWN ADVISORY INC0.13%0.00%33,911--105,463Mar 31, 2024
ALLWORTH FINANCIAL LP0.01%0.00%3,119--9,701,000Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.0.04%-9,116--28,351,000Mar 31, 2024

As of Mar 31 2024, Rani Therapeutics's biggest institutional seller is ALPHA SQUARE GROUP S, LLC. The company sold -25.55K shares of RANI, valued at $103.88K.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
XR SECURITIES LLC0.12%0.00%30,90030,900100.00%96,099Mar 31, 2024
HRT FINANCIAL LP0.09%0.00%22,58722,587100.00%70,000Mar 31, 2024
CITADEL ADVISORS LLC0.06%-14,40014,400100.00%44,784Mar 31, 2024
CITADEL ADVISORS LLC0.04%-10,03210,032100.00%31,200Mar 31, 2024
CITADEL ADVISORS LLC0.03%-7,4007,400100.00%23,014Mar 31, 2024

Rani Therapeutics's largest new institutional shareholder by number of shares is XR SECURITIES LLC, purchased 30.90K shares, valued at $96.10K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
IAG WEALTH PARTNERS, LLC----1,005-100.00%-Mar 31, 2024

Rani Therapeutics's largest sold out institutional shareholder by shares sold is IAG WEALTH PARTNERS, LLC, sold -1.00K shares, valued at -, as of undefined.

Rani Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.04%17,809--Dec 31, 2023
BRIDGEWAY FUNDS INC0.02%51,500--Dec 29, 2023
VANGUARD INDEX FUNDS0.00%746,074112,94417.84%Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%124,02616,75315.62%Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%14,248--Dec 31, 2023
SCHWAB CAPITAL TRUST0.00%2,793--Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%3,9443,944-Jan 31, 2024
GOLDMAN SACHS TRUST0.00%4,103--Feb 29, 2024
Goldman Sachs ETF Trust0.00%2,119--Feb 29, 2024
VARIABLE INSURANCE PRODUCTS FUND II0.00%280--Dec 31, 2023
PROSHARES TRUST0.00%2,060--Feb 29, 2024
iSHARES TRUST0.00%127,073--Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS0.00%3,926--Feb 29, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%594--Dec 31, 2023

Rani Therapeutics's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 17.81K shares, compromising 0.04% of its total assets.

Rani Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 243715.63%
31 Dec, 2332-3.03%
30 Sep, 2333-8.33%
30 Jun, 2336-
31 Mar, 23365.88%
31 Dec, 22346.25%
30 Sep, 223218.52%
30 Jun, 222717.39%
31 Mar, 22239.52%
31 Dec, 212140.00%
30 Sep, 2115-

As of 31 Mar 24, 37 institutions are holding Rani Therapeutics's shares, representing an increase of 15.63% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 243,115,1055.54%
31 Dec, 232,951,624-8.01%
30 Sep, 233,208,534-0.58%
30 Jun, 233,227,28610.20%
31 Mar, 232,928,594-0.67%
31 Dec, 222,948,381-7.13%
30 Sep, 223,174,62512.37%
30 Jun, 222,825,03510.49%
31 Mar, 222,556,816106.04%
31 Dec, 211,240,93913.05%
30 Sep, 211,097,738-

Rani Therapeutics (RANI) has 3.12M shares outstanding as of 31 Mar 24, up 5.54% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2412.21%9.15%
31 Dec, 2311.55%7.21%
30 Sep, 2312.66%7.74%
30 Jun, 2312.79%9.50%
31 Mar, 2311.60%8.28%
31 Dec, 2211.84%7.03%
30 Sep, 2212.97%9.66%
30 Jun, 2211.59%8.13%
31 Mar, 2211.94%29.30%
31 Dec, 216.38%20.02%
30 Sep, 215.65%-

As of 31 Mar 24, Rani Therapeutics is held by 12.21% institutional shareholders, representing a 9.15% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 2412140.00%
31 Dec, 235-44.44%
30 Sep, 239-43.75%
30 Jun, 231614.29%
31 Mar, 2314-6.67%
31 Dec, 2215-6.25%
30 Sep, 221623.08%
30 Jun, 221318.18%
31 Mar, 2211-26.67%
31 Dec, 2115-
30 Sep, 2115-

12 institutional shareholders have increased their position in RANI stock as of 31 Mar 24 compared to 5 in the previous quarter (a 140.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 245-16.67%
31 Dec, 236-14.29%
30 Sep, 237250.00%
30 Jun, 232-50.00%
31 Mar, 234-50.00%
31 Dec, 228-
30 Sep, 22833.33%
30 Jun, 226-14.29%
31 Mar, 227250.00%
31 Dec, 212-
30 Sep, 21--

5 institutional shareholders have reduced their position in RANI stock as of 31 Mar 24 compared to 6 in the previous quarter (a -16.67% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 243715.63%3,115,1055.54%12.21%9.15%12140.00%5-16.67%
31 Dec, 2332-3.03%2,951,624-8.01%11.55%7.21%5-44.44%6-14.29%
30 Sep, 2333-8.33%3,208,534-0.58%12.66%7.74%9-43.75%7250.00%
30 Jun, 2336-3,227,28610.20%12.79%9.50%1614.29%2-50.00%
31 Mar, 23365.88%2,928,594-0.67%11.60%8.28%14-6.67%4-50.00%
31 Dec, 22346.25%2,948,381-7.13%11.84%7.03%15-6.25%8-
30 Sep, 223218.52%3,174,62512.37%12.97%9.66%1623.08%833.33%
30 Jun, 222717.39%2,825,03510.49%11.59%8.13%1318.18%6-14.29%
31 Mar, 22239.52%2,556,816106.04%11.94%29.30%11-26.67%7250.00%
31 Dec, 212140.00%1,240,93913.05%6.38%20.02%15-2-
30 Sep, 2115-1,097,738-5.65%-15---

Rani Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell83,724$9.44$790.35K127,788
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell58,334$13.21$770.59K41,666
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell171,500$5.44$932.96K34,300
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell83,724$9.44$790.35K127,788
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell73,150$13.21$966.31K52,250
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell171,500$5.44$932.96K34,300
Dec 19, 2023Ausiello Dennis Adirector-D-ReturnSell15,423$9.44$145.59K63,894

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 22, 2024McKinley Kateofficer Chief Business OfficerA-AwardBuy323,500$3.60$1.16M323,500
Mar 22, 2024Hashim Mirofficer Chief Scientific OfficerA-AwardBuy323,500$3.60$1.16M323,500
Mar 22, 2024Groen Ericofficer General CounselA-AwardBuy323,500$3.60$1.16M323,500
Mar 22, 2024Imran Talatdirector, officer Chief Executive OfficerA-AwardBuy1,085,000$3.60$3.91M1,085,000
Mar 22, 2024Sanford Svai Sofficer Chief Financial OfficerA-AwardBuy323,500$3.60$1.16M323,500
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerA-AwardBuy171,500$2.84$487.06K171,500
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell83,724$9.44$790.35K127,788
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerA-AwardBuy83,724$2.84$237.78K83,724
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerA-AwardBuy58,334$2.84$165.67K58,334
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell58,334$13.21$770.59K41,666
Dec 19, 2023Sanford Svai Sofficer Chief Financial OfficerD-ReturnSell171,500$5.44$932.96K34,300
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerA-AwardBuy171,500$2.84$487.06K171,500
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell83,724$9.44$790.35K127,788
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerA-AwardBuy83,724$2.84$237.78K83,724
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerA-AwardBuy73,150$2.84$207.75K73,150
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell73,150$13.21$966.31K52,250
Dec 19, 2023Hashim Mirofficer Chief Scientific OfficerD-ReturnSell171,500$5.44$932.96K34,300
Dec 19, 2023Ausiello Dennis Adirector-A-AwardBuy101,276$2.84$287.62K101,276
Dec 19, 2023Ausiello Dennis Adirector-D-ReturnSell15,423$9.44$145.59K63,894
Dec 19, 2023Ausiello Dennis Adirector-A-AwardBuy15,423$2.84$43.80K15,423

The last insider sell of Rani Therapeutics's stock was made by Sanford Svai S on Dec 19 2023, selling 83,724 shares at $9.44 per share (valued at $790.35K).

Rani Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20245--
Q4 20233427125.93%
Q3 2023---
Q2 202327--
Q1 2023294725.00%
Q4 202231--
Q3 20222450.00%
Q2 202210--
Q1 2022137185.71%
Q4 202111100.00%
Q3 202163616.67%

5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Rani Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q4 202381800.00%
Q3 2023---
Q2 202319--
Q1 202321--
Q4 202231--
Q3 2022-2-
Q2 2022---
Q1 2022---
Q4 2021---
Q3 20213--

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Rani Therapeutics's stocks.

Rani Therapeutics Peer Ownership


TickerCompany
SRZNSurrozen, Inc.
PMVPPMV Pharmaceuticals, Inc.
TYRATyra Biosciences, Inc.
BMEABiomea Fusion, Inc.
CRVSCorvus Pharmaceuticals, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
VINCVincerx Pharma, Inc.
SQZSQZ Biotechnologies Company
TNYATenaya Therapeutics, Inc.
VIRXViracta Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
ALXOALX Oncology Holdings Inc.
TCONTRACON Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
PHVSPharvaris N.V.
CABACabaletta Bio, Inc.
TRVITrevi Therapeutics, Inc.
TARAProtara Therapeutics, Inc.
MOLNMolecular Partners AG
LYRALyra Therapeutics, Inc.
VCNXVaccinex, Inc.

RANI Ownership FAQ


Rani Therapeutics is owned by institutional shareholders (12.21%), insiders (48.88%), and public (38.91%). The largest institutional shareholder of Rani Therapeutics is VANGUARD GROUP INC (2.69% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.04% of total shares).

Rani Therapeutics's major institutional shareholders are VANGUARD GROUP INC, NAN FUNG GROUP HOLDINGS LTD, UNITED SERVICES AUTOMOBILE ASSOCIATION, ALPHABET INC., and STIFEL FINANCIAL CORP. The top five shareholders own together 8.79% of the company's share outstanding.

As of Mar 2024, there are 37 institutional shareholders of Rani Therapeutics.

VANGUARD GROUP INC owns 685.3K shares of Rani Therapeutics, representing 2.69% of the company's total shares outstanding, valued at $2.13M (as of Mar 2024).

As of Mar 2024, NAN FUNG GROUP HOLDINGS LTD holds 493.58K shares of Rani Therapeutics (RANI), compromising 1.94% of the company, valued at $1.54M.

UNITED SERVICES AUTOMOBILE ASSOCIATION is the third largest holder of Rani Therapeutics. The company owns 481.3K of the company's shares outstanding (worth $1.5M).